Abstract #4604

DCE-MRI Tumor Volumetric Changes Predict Response to Neoadjuvant Immunochemotherapy in Triple Negative Breast Cancer Patients

Gaiane Margishvili Rauch¹, Tanya Moseley², Mary Guirguis², Gary Whitman², Rosalind Candelaria², Jessica Leung², Miral Patel², Jia Sun³, Huong Le-Petross², Deanna Lane², Marion Scoggins⁴, Frances Perez², Rania M Mohamed⁵, Zhan Xu⁶, Sanaz Pashapoor⁷, Jong Bum Son⁶, Ken-Pin Hwang⁸, Huiqin Chen³, Peng Wei³, Debu Tripathy⁹, Wei Yang², Clinton Yam⁹, Jingfei Ma⁸, and Beatriz Adrada²

¹Abdominal and Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ²Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ³Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁴Radiology - Breast Imaging, UT Southwestern Medical Center, Dallas, TX, United States, ⁵Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁶Imaging Physics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁷Breast Imaging - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁸Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ⁹Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Synopsis

Keywords: Breast, Breast, Treatment response prediction, DCE-MRI, biomarkers

Motivation: There is unmet need for noninvasive biomarkers for neoadjuvant immunochemotherapy (NICT) response prediction in triple negative breast cancer (TNBC) to guide least toxic and most effective treatment regimens.

Goal(s): To evaluate if DCE-MRI tumor volume changes measured early during NICT can predict treatment response.

Approach: DCE-MRI tumor volume reduction (TVR) was calculated in 64 TNBC at baseline, after 2 and 4 cycles of NICT and correlated with surgical pathology using ROC analysis.

Results: DCE-MRI TVR after 2 cycles of NICT was able to predict pCR with AUC of 0.71 (95%CI:0.57-0.84) and after 4 cycles with AUC of 0.81 (95%CI:0.69-0.92).

Impact: DCE-MRI tumor volume changes early during neoadjuvant immunochemotherapy can identify triple negative breast cancer patients with high/low likelihood of pathologic complete response, triaging them to appropriate management for de-escalation trials versus targeted therapies, avoiding unnecessary toxicity of ineffective treatment.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.